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"I believe in evidence. I believe in observation, measurement, and 
reasoning, confirmed by independent observers. I'll believe anything, no 
matter how wild and ridiculous, if there is evidence for it. The wilder 
and more ridiculous something is, however, the firmer and more solid the 
evidence will have to be." 
Isaac Asimov (1997) The Roving Mind. Prometheus Books. p. 349. 
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Abstract 
Oxygen is the most abundant element on earth; essential for survival, and physiology 
of living organisms so called oxygen homeostasis. Organisms and cells have developed 
number of adaptive mechanisms to survive in oxygen-deprived (hypoxia) conditions.  
Hypoxia-inducible factor-1 (HIF-1a) serves as a master regulator of these adaptive 
processes.  It binds directly to the hypoxia responsive element in the promoter region 
of hypoxia-inducible genes.   Upregulation of HIF-1a has been tightly related to 
carcinogenesis, metastasis and angiogenesis. With a growing understanding of the HIF-
1 pathway, inhibition and stimulation of its transcriptional activity via small molecules 
has become an attractive goal in disease therapeutics.  
 In light of above information and my interest in hypoxia signaling, I have established a 
cell-based screening system to search for phytochemicals with hypoxia-modulating 
effects by recruiting hypoxia responsive element (HRE) driven luciferase reporter, and 
identified few bioactive natural compounds as pro-hypoxia and anti-hypoxia factor.  
In the first study, I have chosen a pro-hypoxia molecule (C-021) Caffeic acid phenethyl 
ester (CAPE), identified as pro-hypoxia factor, which is known as major component of 
New Zealand propolis, known for a variety of health promoting and therapeutic 
potentials. Several studies shown selective toxicity to cancer cells while treated with 
CAPE. I have investigated the anticancer and anti-metastasis activities of CAPE and its 
direct binding partner. Initial molecular docking studies suggested that CAPE is 
showing capability of mortalin-p53 complexes disruption.  Invitro evidences clearly 
demonstrated that CAPE disrupts mortalin-p53 complexes which lead to nuclear 
translocation and activation of p53 resulting in growth arrest in cancer cells.  In 
addition, CAPE-treated cells shown reduction in mortalin and several other key 
regulators of cell migration which is accountable for its anti-metastasis activity. Here, 
I have identified CAPE as a new anti-mortalin molecule.  
Most drugs used as anticancer agents to treat various cancers like lung, breast, 
pancreatic etc. also promote drug resistance and finally unlimited tumor growth. In 
	 4 
extension of this study, I tried to identify the effect of CAPE on drug resistance in 
cancer cells. Drug resistance is closely related to cancer cell stemness, that is acquired 
along with resistance to various anticancer agents. Mortalin/mthsp70, a member of 
Hsp70 family, has been shown to promote proliferation, metastasis and angiogenesis, 
and downregulate apoptotic signaling. Mortalin/mtHsp70 is a member of Hsp70 family 
of proteins.  Enriched in a large variety of cancers, it has been shown to contribute to 
the process of carcinogenesis by multiple ways including, inactivation of tumor 
suppressor p53 protein, deregulation of apoptosis and activation of EMT signaling.  
As I already established CAPE as an anti-mortalin molecule, here I found that 
upregulation of mortalin contributes to cancer cell stemness by using a mortalin 
overexpression model. Several cancer cell stemness markers, such as ABCG2, OCT4, 
CD133, ALDH1, CD9, MRP1 and connexin were upregulated in mortalin 
overexpressing cells that showed higher ability to form spheroids. These cells also 
showed higher migration and were less responsive to a variety of cancer 
chemotherapeutic drugs.  Of note, knockdown of mortalin by specific shRNA or 
CAPE sensitized these cells to all the drugs used in this study.  I used low doses of 
anti-mortalin molecules, MKT-077 (already known) and CAPE and found that these  
caused similar sensitization of cancer cells to chemotherapeutic drugs and hence are 
suggested as potential candidates for effective cancer chemotherapy.  
I provide experimental evidence that the low doses of CAPE, that did not cause 
cytotoxicity or anti-migratory effect, rather activated HIF-1a and inhibited stress-
induced protein aggregation which is a cause in diseases like Alzheimer etc. 
In second study, I have chosen (C-024) Withaferin-A (Wi-A) identified as anti-hypoxia 
molecule, a natural compound from Withania somnifera (Ashwagandha) plant, an 
important medicinal plant, is commonly known as “Indian ginseng” or “winter cherry”. 
In previous studies, Nuclear Factor-κB (NF-κB) a redox-sensitive transcriptional factor 
identified as major transcription factor responding to cellular stress. So perhaps it will 
not surprising that it is activated by hypoxia, or decreased oxygen availability. 
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Withaferin-A was shown to inhibits NF-kB (nuclear factor kappaB) in previous studies. 
More recently, NF-kB binding to this site in the HIF-1a promoter has been shown also 
under hypoxic conditions. Thus, these two major pathways regulating the responses to 
inflammation and oxidative stress on the one hand, and hypoxia on the other hand, 
appear to be intimately linked. Constitutional activation of NFκB in cancer cells has 
been related to their anti-apoptosis and continued proliferation characteristics. Other 
than these facts, NF-kB also showed to have a major role in cellular senescence. 
Hypoxia modulates senescence in various ways. Excess oxygen expose to mitochondria 
produces reactive oxygen species (ROS) that can promote senescence. Hypoxia leads 
to the stabilization of HIF, which impacts many pathways that can affect senescence. 
So, I recruited low dose of Wi-A that caused slow growth arrest in cancer cells, and 
were relatively safe for normal cells in short term (2-3 days) viability assays.  
Consistently, I detected nuclear translocation of NF-κB and activation of p38MAPK in 
cancer, but not in normal, cells. Experimental data revealed an increased level of 
phosphorylated IκBα in Wi-A treated cells, suggesting an activation of IKK complex 
that was supported by nuclear translocation of NF-κB. It was supported by 
downregulation of NF-κb effectors, Cyclin D and Cyclin E. I further investigated the 
DNA damage signaling pathway and found that Wi-A caused upregulation of CARF 
(Collaborator of ARF) demonstrating an activation of DNA damage and oxidative 
stress response in both cancer and normal cells.  In line with this, and in contrast to 
selective activation of NF-κB and p38MAPK in cancer cells, growth arrest and 
senescence-determining proteins p21WAF1, p16INK4A, hypophoshorylated-pRB showed 
upregulation both in cancer and normal cells. Indeed, long term (4-8 days) viability 
assays revealed induction of senescence both in cancer and normal cells demonstrating 
that Wi-A-induced senescence is mediated by multiple pathways in which CARF-
mediated DNA damage and oxidative stress play a major role. 
	 6 
 Taken together, these results provide a unique way to identify new small molecules to 
modulate hypoxia. For future perspective, these candidates could be used as potential 
therapeutic target for oxidative stress related diseases. 
Keywords: cancer, HIF 1 a, stemness, drug resistance, senescence. 
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Chapter-I 
1. Introduction 
1.1 Hypoxia and Its molecular mechanism 
Organism and cells have developed number of adaptive mechanism to survive in 
oxygen-deprived (hypoxia) conditions. Oxygen homeostasis is really required for 
normal cellular function. (Fig. 1-1) At the organism level, hyperventilation, 
neovascularization and increased erythropoiesis in combination deliver oxygen from 
the atmosphere to the tissues. Whereas at the cellular level, glycolysis activation, 
rapid increases in glucose uptake, cell survival proteins induction and transcriptional 
induction at gene levels are main survival or adaptation mechanism (1). It mainly 
regulates through a transcriptional factor, hypoxia-inducible factor-1 (HIF-1a) which 
binds with the hypoxia responsive element and regulates about 40 hypoxia-inducible 
genes, directly (2). HIF is a heterodimer consisting a and b subunits, in which 
a  subunit is oxygen regulated, expressed in all human cell types whereas b subunit   
binds with a  subunit in the nucleus and activates hypoxia signaling through 
recruitment of p300 and CBP. (3).  
In normoxia condition, HIF-1 a is degraded by pVHL (Von Hippel-Lindau tumor 
suppressor protein, a part of E3 ubiquitin ligase protein complex by ubiquitination and 
proteosomal degradation or by Factor Inhibiting HIF (FIH) by inhibition of its 
interaction with co-activator p300/CBP. (i) The mechanism underlying in normoxia, 
prolyl hydroxylase domain enzymes (PHDs) hydroxylate Proline564 or Proline402 on 
HIF-1 a  with the help of iron, 2-oxoglutarate (2-OG) and molecular oxygen as a 
substrate and recognized by pVHL, resulting inhibition of enzymatic reaction of prolyl 
hydroxylation precluding the binding of pVHL and stabilize HIF-1 a (4). Another 
mechanism in which FIH hydroxylates, asparginyl 803 on HIF-1 a   with the help of  
2-OG and iron and inhibits its HIF-1 alpha interaction with its co-activator 
p300/CBP(5;6).  Prolyl hydroxylation (P564 or P402) is more sensitive than 
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asparaginyl hydroxylation (A803) (another hydroxylation site on HIF) to inhibition by 
iron chelators (7).  
 
1.2 Hypoxia in cancer 
Cancer is generally characterized as a disease of cell proliferation and spreading 
of abnormally growing cells to other parts of the body. It continues to be a killer 
throughout the world although past decade has seen rapid developments in cancer 
diagnostics and treatment. The primary reason for treatment failure and high mortality 
has been attributed to the highly invasive nature of cancer cells resulting in rapid cancer 
progression and metastasis. Hypoxia-inducible transcription factor (HIF) has long been 
linked to malignant tumor phenotypes in different types of cancers and known as 
transcriptional factor (8-14). Hypoxia appeared in tumors through the uncontrolled 
oncogene-driven proliferation of cancer cells in the absence of sufficient blood and 
oxygen supply, which increase proliferation of cancer cells, resulting tumor quickly 
exhausts the nutrient and oxygen supply from the normal vasculature, and becomes 
hypoxic (Fig. 1-2). The major regulator acts as a heterodimer (HIF-1α and HIF-1b).  
Whereas HIF-1α is regulated by oxygen, HIF-1b is constitutively expressed (15). A 
Per-ARNT-Sim (PAS) domain is present in both the subunits. It is centrally involved 
in oxygen homeostasis and activated in a large majority of tumors (16;17). Under 
normoxia conditions, α-subunit undergoes hydroxylation by Proline-hydroxylase-2. 
The hydroxylated HIF-1α undergoes degradation by proteasome mediated degradation 
pathway involving tumor suppressor VHL (von Hippel–Lindau protein) (18). Another 
oxygen-dependent modification (Asparaginyl hydroxylation) catalysed by dioxygenase 
called Factor Inhibiting HIF-1α (FIH-1) occurs in the C-terminal (Asn803) 
transactivation domain of HIF-1α (13;19). Under hypoxia conditions that prevent HIF-
1α hydroxylation and degradation, HIF-1α accumulates, translocates to the nucleus, 
dimerizes with HIF-1b, and transactivates several effector proteins (20;21).  It is also 
regulated by CREB binding protein (CBP) and p300 that interact with the carboxy-
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terminal transactivation domain of HIF-1α and act as its transcriptional co-activators 
(22) (Fig. 1-3). It has been shown that hydroxylation at Asn803 under normoxic 
conditions inhibits interactions of HIF-1α to CBP and p300 (6). Since HIF-1 is a key 
driver of hypoxia signalling, involved in cancer progression in one hand and several 
brain-disorders on the other, the identification of HIF-modulating drugs/factors and 
molecular mechanism of their action has been warranted for disease therapeutics (11).   
 
1.3 Hypoxia in oxidative stress and stress protection 
Under normal cellular conditions there is a constant balancing act between the oxygen 
concentration and reactive oxygen species (ROS) and their elimination is done by 
antioxidant system including enzymes such as superoxide dismutase, glutathione 
peroxidase, and catalase.  In general, low levels of ROS can delay cellular signaling 
and disrupt intracellular reactions, while high levels of ROS create oxidative stress 
which can lead to the improper oxidation of lipids, proteins and DNA damage resulting 
eventually resulting in apoptosis, necrosis, and other cellular damage. Oxidative stress 
during hypoxia may sound self-contradictory (23). Oxidative stress can be 
accommodated in cells in lower or higher oxygen tension. (Fig. 1-4) The hypoxic cell 
relies on anaerobic respiration through glycolysis to generate ATP, whereas low oxygen 
supply supports some level of oxidative production of ATP through the tricarboxylic 
acid cycle and electron transport chain (ETC). Electrons leakage from the 
mitochondrial ETC generate an excess of reactive oxygen species (ROS), i.e., oxidative 
stress. Reoxygenation or high oxygen levels following severe hypoxia further 
exaggerate ROS generation (23). So, a balance is must in oxygen tension to support 
normal cellular functions. 
In previous studies, PHD which is a hydroxylation partner of HIF, inhibition 
consistently provide neuroprotection in various neurological disease models e.g. stroke 
(24;25) Parkinson’s disease (PD) (26), Oxidative stress (27), Alzheimer’s disease (AD) 
(26;28;29) and mitochondrial dysfunction (30). PHD’s have been recognized as direct 
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targets for iron chelators such as desferoxamine which shown beneficial in many 
neurological disorders with the neuroprotective effects (24).  
Wei et al (31) reported that CAPE prevents neonatal hypoxic-ischaemic (HI) insult 
caused brain injury in rat pups. The main mechanism underlying of neuroprotection by 
CAPE was direct inhibition of HI induced inflammation and neuronal death.   Other 
than these reports, CAPE has been reported as a potent inhibitor of HIF prolyl 
hydroxylase (HPH), a key enzyme for von Hippel-Lindau-dependent HIF-1 
a degradation.  Inhibition of HPH leads to induction of HIF-1 a  protein and 
transactivating HIF-1 targeting genes VEGF (Vascular Endothelial Growth Factor) and 
heme oxygenase-1 (HO-1), which play a protective role in I/R injury (8). Since HIF-1 
a regulation is really important and its link with oxidative stress relates pathology of 
brain disorders like Alzheimer’s and Parkinson’s etc., so there is a need of identification 
of small molecule regulators of hypoxia. 
 
1.4  Cancer metastasis and drug resistance 
Recent investigations in cancer diagnostic and therapeutic have increased the success 
rate and cancer patient’s survival.  However, metastasis cancer treatment is still a 
challenge. Cancer metastasis involves a process including translocation of cancer cells 
from their primary site and travel at either the surrounding or distant tissues by invasion 
through the extracellular matrix (ECM) or the blood/lymph streams, respectively. It is 
a complex multi-step process which involves several factors that enable cancer cells to 
acquire aggressiveness, invasiveness and intravasate into circulatory system, survive in 
the blood or lymph circulation, form microvasculature and extravagate to form tumor 
mass at distant organs (32-34). (Fig. 1-4) These also include several processes at 
cellular level including epithelial-to-mesenchymal transition (EMT), motility, adhesion 
and invasiveness that are regulated by oncogene activation, proteases activation and 
other tumor-microenvironment components activation including hypoxia and 
inactivation of tumor suppressor proteins and apoptosis-mediating factors (35-38). 
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When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive 
responses in order to sustain this condition and survive. There is a define levels of 
hypoxia called acute and chronic hypoxia. In general tumor metastasis, acute hypoxia 
stabilizes within the microenvironment and develop vascularization leads to metastasis. 
But (39) If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is 
also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 
(hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The 
p53 protein is a transcription factor, which is rapidly stabilized by cellular stresses and 
which has a major role in the cell responses to these stresses. In the tumor 
microenvironment, oxidative stress potentiates not only necrosis but also limiting O2 
diffusion (Hypoxia) within the tumors, which decreased sensitivity to cell death signals 
and increased signaling to promote angiogenesis and metastasis (40). This stress 
conditions particularly responsible in cancer stem cells to escape from the radiotherapy 
and chemotherapy. Many Heat shock proteins (hsp’s) are up regulated in cells while 
exposed to different environmental stress.  Mortalin a mitochondrial protein also 
named as Glucose-regulated protein (Grp) 75 is a member of HSP70 family, known for 
p53 interaction partner in cancer cells and a selective for cancer therapy (41). Mortalin 
plays an important role in human carcinogenesis by enhancing proliferation, apoptosis 
protection and angiogenesis (42). Mortalin’s role in hemolysis and the ninth component 
of complement (C9) polymerization suggests that it promotes resistance in cancer cells 
(43). Elevated levels of mortalin expression increases cancer cell resistance to cisplatin-
induced cytotoxicity and identify mortalin as a potential target in drug-resistant ovarian 
cancer (44). (Fig. 1-5) Chemotherapeutic drugs and pro-cancers signaling pathways are 
correlated with each other’s. (Fig. 1-4) However, the major concern is most of the 
available drugs also target the non-cancer normal dividing cells in the body resulting in 
undesired adverse side-effects including low-immune response, hair loss, fatigue, 
nausea and hormone-imbalance.  In addition, most of the anticancer drugs show low 
efficacy for metastatic cancer cells resulting either treatment failure or tumor relapse.  
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Taken together, Chemoresistance and radioresistance in cancer cells and nonspecific 
toxicity of chemical drugs towards normal cells are the major hurdles the cancer 
treatment, so there is a need of identification of new small molecules, which can revert 
chemoresistance with no cytotoxic effect on normal cells. 
 
 
1.5 Thesis structure and overall impact 
This whole study provides a novel method to identify new molecular targets (natural 
compounds) for hypoxia regulation and link to oxidative stress related diseases like 
stress, aging, cancer and inflammation. This work provides a new strategy for the 
development of new screening method and identification of new hypoxia target 
molecules which could be further modified chemically in the future for better 
therapeutic purpose. 
 
 
Chapter 1 Introduction 
In this chapter, the major signaling which is hypoxia is described with informative 
background and tried to connect hypoxia with different oxidative stress related diseases. 
The purpose and motivation are also addressed in this chapter for better understanding 
of hypoxia and related diseases. 
 
Chapter 2 Screening of drug library by HRE driven luciferase reporter system- 
Identification of CAPE (C-021) as prohypoxia factor and its anti-stress effect by 
stress models. 
In this chapter, CAPE is defined as pro-hypoxia factor by biochemical approach. 
Together, pro-hypoxia effect of CAPE is described on cell stress models.  
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Chapter 3 Identification of CAPE (C-021) as anti-mortalin molecule and studied 
its effect on drug resistance. 
In this chapter, CAPE is identified as anti-mortalin molecule and described its potential 
anti-metastasis activity with help of other supportive metastasis markers. In addition, 
cancer stem cell model has been established by mortalin overexpression cell lines. For 
same purpose drug resistance properties and stemness markers have been studied.  
 
Chapter 4 Screening of drug library by HRE driven luciferase reporter System-
Identification of Withaferin-A (C-024) as anti-hypoxia factor and its major role in 
NF-kB signaling.  
In this chapter, lower dose effect of Wi-A has been shown on NF-kB signaling and 
senescence which is related to oxidative stress. 
 
Chapter 5 Conclusions and future researches 
In this chapter, the main results are summarized. In particular, the future research 
points were also directed. 
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     Fig. 1- 1 A general description of oxygen homeostasis and its effect on diseases 
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                   Fig. 1- 2 Hypoxia and related cellular mechanism  
 
 
 
 
 
 
 
 
HIF-1a is a master regulator in 
Hypoxia signaling 
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              Fig. 1- 3 Oxygen driven regulation of hypoxia 
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        Fig. 1- 4 Oxygen tension and its impression on various pathologies 
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     Fig. 1- 5 Description of mortalin role from normal cell function 
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Chapter 2 
 Screening of drug library by HRE driven luciferase 
reporter system- Identification of CAPE (C-021) as 
prohypoxia factor and its anti-stress effect by stress 
models. 
2.1 Introduction 
Cancer is generally characterized as a disease of cell proliferation and spreading of 
abnormally growing cells to other parts of the body. It continues to be a killer 
throughout the world although past decade has seen rapid developments in cancer 
diagnostics and treatment. The primary reason for treatment failure and high mortality 
has been attributed to the highly invasive nature of cancer cells resulting in rapid cancer 
progression and metastasis. Hypoxia-inducible transcription factor (HIF) has long been 
linked to malignant tumor phenotypes in different types of cancers (1-7). It is a 
transcription factor that acts as a heterodimer (HIF-1α and HIF-1b).  Whereas HIF-1α 
is regulated by oxygen, HIF-1b is constitutively expressed (8). A Per-ARNT-Sim 
(PAS) domain is present in both the subunits. It is centrally involved in oxygen 
homeostasis and activated in a large majority of tumors (9;10). Under normoxia 
conditions, α-subunit undergoes hydroxylation by Proline-hydroxylase-2. The 
hydroxylated HIF-1α undergoes degradation by proteasome mediated degradation 
pathway involving tumor suppressor VHL (von Hippel–Lindau protein) (11). Another 
oxygen-dependent modification (Asparaginyl hydroxylation) catalysed by dioxygenase 
called Factor Inhibiting HIF-1α (FIH-1) occurs in the C-terminal (Asn803) 
transactivation domain of HIF-1α (6;12). Under hypoxia conditions that prevent HIF-
1α hydroxylation and degradation, HIF-1α accumulates, translocates to the nucleus, 
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dimerizes with HIF-1b, and transactivates several effector proteins (13;14).  It is also 
regulated by CREB binding protein (CBP) and p300 that interact with the carboxy-
terminal transactivation domain of HIF-1α and act as its transcriptional co-activators 
(15). It has been shown that hydroxylation at Asn803 under normoxic conditions 
inhibits interactions of HIF-1α to CBP and p300 (16;17). Since HIF-1 is a key driver of 
hypoxia signalling, involved in cancer progression in one hand and several brain-
disorders on the other, the identification of HIF-modulating drugs/factors and 
molecular mechanism of their action has been warranted for disease therapeutics (4).  
In view of this, I performed a natural drug screening to search for hypoxia-modulating 
effects using cell-based HIF-1α reporter assay, and identified caffeic acid phenethyl 
ester (CAPE) as one of the prohypoxia factors.  
CAPE is a bioactive compound found in many plants (18).  It is a key component of 
propolis obtained from honeybee hives (19-22). The presence of hydroxyl groups in the 
catechol ring of this polyphenol has been ascribed to be responsible for many of its 
biological activities, such as anticancer, anti-microbial, anti-viral, neuroprotective and 
anti-inflammatory properties (20-24).  Choi et al. reported that CAPE is a potent 
inhibitor of HIF prolyl hydroxylase (HPH-2) raising the question on its relevance to 
modulate hypoxia signaling in cancer cells (1). Roos et al. also reported the stabilization 
of HIF-1α and subsequent induction of heme oxygenase-1 (HO-1) during CAPE 
induced growth arrest in PDGF-activated vascular smooth muscle cells (25). In view of 
these information and identification of CAPE as a candidate pro-hypoxia factor in our 
screenings, I explored the docking potential of CAPE with HIF-1α and FIH-1 (inhibits 
HIF-1α by hydroxylation at Asn803).  I found that whereas CAPE was incapable of 
interacting with HIF-1α, it docked efficiently into the active site of FIH-1.  I provide 
experimental evidence for the prohypoxia activity of CAPE that may be the result of 
attenuation of HIF-1α inhibition by FIH, and its impact on stress-induced protein 
aggregation and cell-migration phenotypes. Furthermore, structural analogues of CAPE 
with stronger activity are reported.   
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2.2 Material and Methods 
2.2.1 Transfection and reagents 
Human osteosarcoma (U2OS) was purchased from JCRB Japan, and cultured in 
DMEM (Life technologies). Transfection was performed using lipofectamine 2000 
(invitrogen) in opti-mem (Gibco, Life Technologies) media. The pGL4-p53-3’UTR 
were gifted from Dr. Chae-Ok Yun (Hanyang University, Seoul, South Korea). GFP-
tagged mortalin MOT/GFP was expressed from pEGFP-C1/mot-2. NaAsO2 (Sodium 
(meta) Arsenite) was purchased from Sigma Aldrich. 
 
2.2.2 Generation of hypoxia responsive cells 
 U2OS cells were transfected with the plasmid expressing luciferase driven by promoter 
containing Hypoxia Response Element (HRE). (Fig. 2-1A) Twenty-four hours post-
transfections, the media was replaced with DMEM supplemented with hygromycin B 
(Roche) (700µg/mL) for 10-15 days.  The clones showing 100- to 1000-folds increase 
in luciferase in fixed and live cell assays were selected. (Fig. 2-1B) The selected clones 
were amplified and established into cells stably expressing hypoxia responsive 
luciferase reporter.   
 
2.2.3 Cell viability assay 
 Vital dye, MTT (molecular probes, Invitrogen) (0.5 mg/ml), was added to the U2OS 
cell culture medium for 4 h in a humidified incubator (37°C and 5% CO2).  MTT-
containing medium was replaced with DMSO (100 µl) to dissolve purple formazan 
crystals. Absorbance of the blue chromogen was observed at 550 nm using 
spectrophotometer (TECAN, Switzerland). The statistical significance of the data was 
calculated from triplicates and 3-4 independent experiments, respectively. 
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2.2.4 Screening for hypoxia modulating natural drugs 
  U2OS-HRE cells were plated in 96-well plates at about 70% confluency. After the 
cells had attached well to the surface, they were treated with phytochemical library (for 
48 h) at sub-toxic doses, determined by independent MTT-based cell viability assays 
as described above. HIF-1 activity in the treated cells was determined by HRE-
dependent luciferase by Dual Luciferase reporter assay system (Promega, Madison, 
WI). Luciferase activity was calculated per microgram protein following the 
manufacturer’s protocol, and reported as the relative activity normalized against 
untreated cells. Three independent experiments were performed for statistical 
significance. 
 
2.2.5 Western blotting 
  Cells were cultured in DMEM in 6 well plates and lysed using 1% Nonidet P-40 buffer 
containing a protease inhibitor cocktail (WAKO). The protein concentrations of whole 
cell lysate were measured by bicinchonic acid assay (BCA) (Thermo Fisher Scientific, 
Rockford, IL). The cell lysates (15-20 µg) were separated in 10% SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore, Billerica, MA).  Blocked membranes were probed with target 
protein-specific primary antibodies, Luciferase (luci17), HIF-1 α (Santa Cruz 
Biotechnology INC. CA, United States), overnight at 4°C. The blots were incubated 
with the following secondary antibodies conjugated to horseradish peroxidase: anti-
mouse IgG (Santa Cruz Biotechnology INC. CA, United States) and developed by 
enhanced chemiluminescence reaction (ECL). 
 
2.2.6 Immunofluorescence staining 
Cells were fixed on a glass coverslip placed in a 12 well culture dish (TPP, Switzerland) 
and fixed with 4% paraformaldehyde in PBS. Later, cells were permeabilized with 0.1% 
	 41 
Triton X-100 for 10mins, blocked with 0.2% BSA/PBS for 1 h and then incubated with 
specific antibody Vimentin, MMP2, MMP7, MMP9, hnRNAP-k (Santa Cruz 
Biotechnology INC. CA, United States) for overnight at 40C. Mortalin antibody was 
raised in our lab. Cells were washed and probed with fluorophore conjugated Goat-anti 
mouse secondary antibody (molecular probes, Invitrogen). Counter staining was 
performed with Hoechst 33342 (Sigma) for 10 mins in dark, then coverslips visualized 
by Carl Zeiss microscope (Axiovert 200 M, Tokyo, Japan).  
 
2.2.7 RNA isolation and cDNA synthesis 
 Total RNA was extracted from U2OS and U2OS-HRE cell lines by using TRIzol 
Reagent (Life Technologies) following supplier-described protocol. Quality and 
quantity were determined by spectrophotometry method (Nano Drop, 1000 
spectrophotometer).  For cDNA synthesis, total RNA (1 µg) was reverse-transcribed 
into cDNA using Quantitect Reverse Transcriptase Kit (QIAGEN) following the 
manufacture’s protocol.  cDNA was stored at -20oC for PCR. 
 
2.2.8 Quantitative real-time PCR 
 Gene expression was quantified by quantitative real time PCR using Syber Select 
Master mix (Applied Biosystem, Life Technologies), luciferase specific primers (F-5’-
GGACTTGGACACCGGTAAGA-3’ and R-5’-CTTGTCGATGAGAGCGTTTG-3’), 
HIF-1a specific primers (F-5’-GTTTACTAAAGGACAAGTCACC-3’ and R-5’-
TTCTGTTTGTTGAAGGGAG-3’ and EcoTM Real-Time PCR System (Illumina, San 
Diego, CA). Relative level of expression of target gene was normalized against the 
internal control 18S by ∆CT method.  An amplification plot between fluorescence 
signals and cycle number was plotted and the mean values in the triplicated samples of 
targeted genes and internal control 18S were calculated.  The relative quantitative 
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value was expressed as 2-∆CT.  Statistical significance of the results was calculated from 
three independent experiments. 
 
2.2.9 Effect of CAPE on cell migration and growth of cancer cells: wound-scratch  
assays   
The in vitro migration capability of U2OS cells with or without CAPE treatment was 
observed with a wound-scratch assay. The cells were seeded in a 6-well plate and 
wounded by uniformly scratching the cells with a pipette tip. Cells were washed several 
times with PBS to remove damaged cells, and continue culture on either the control or 
CAPE-supplemented medium, respectively. The time of wound scratching was taken 
as time 0. Movement of cells into the scratched area was captured during next 24 h, up 
to 72-96 h under a phase contrast microscope with a 10 X phase objective.  
 
2.2.10 Effect of CAPE in stress-induced protein aggregation 
  Sodium arsenite-based aggregation-deaggregation model was used.  U2OS cells 
(4X103/well) stably expressing mortalin-GFP (U2OS-mot-GFP) were seeded in 96-
well plates for overnight followed by treatment with sodium arsenite (20 µM) for 24 h. 
Cells were recovered either in normal culture media or the one supplemented with 
CAPE for 24-48 h. Cell viability was determined by MTT assay as described above.  
Statistical significance of results was determined from 3-4 independent experiments 
including triplet or quadruplet sets in each experiment. For immunofluorescence, same 
method was adopted in 12 well plates with coverslips. 
For heat-shock experiment, cells were seeded in 6 well plate and transfected with 
pGL4-p53-3’UTR for 24 Hrs. After 24 Hrs. cells were then incubated at 420 C 
temperature and 5% CO2 for 2 Hrs. for heat shock. Post 2 Hrs. stress, media was 
changed with or without CAPE for next 48 Hrs. At the end, Cells were harvested and 
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lysed to measure luciferase activity as described earlier. For immunofluorescence, same 
method was adopted in 12 well plates with coverslips. 
 
2.2.11 Statistical analysis 
  All the experiments were performed in triplicate. Data are expressed as mean ±SEM 
of triplicate experiments.  Unpaired t-test (GraphPad Prism GraphPad Software, San 
Diego, CA) has been performed to determine the degree of significance between the 
control and experimental samples. Statistical significance was defined as p-values (*), 
where *<0.05, **<0.01, ***<0.001 represented significant, very significant and very 
very significant, respectively. 
 
2.3 Results and Discussion 
2.3.1 Identification of CAPE as a prohypoxia factor 
  I investigated hypoxia-modulating potential of 60 purified phytochemicals by Hypoxia 
Responsive Element (HRE) driven luciferase in stably transfected cells (as described in 
Material and Methods and Fig. 2-1A, B).  Cells were treated with sub-toxic doses, 
determined by independent experiments (MTT assay and morphological observations), 
of phytochemicals (data not shown). Through three rounds of screenings, I identified 5 
prohypoxia and 4 anti-hypoxia compounds. (Fig. 2-1C) CAPE was identified as one of 
the prohypoxia factors. I investigated dose-dependent effect of CAPE on HRE-
luciferase activity in comparison to a standard pro-hypoxia drug, cobalt chloride 
(CoCl2).  As shown in Fig. 2-2A, HRE-Luciferase activity showed dose dependent 
increase when cells were treated with sub-toxic doses of CAPE (5-15 µM).  Of note, 
the effect of CAPE was stronger than CoCl2, effective at 50-150 µM.  Consistent with 
luciferase reporter assays, qPCR for luciferase showed increase in CAPE- and CoCl2-
treated cells (Fig. 2-2B). Detection of luciferase protein by immunofluorescence using 
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anti-luciferase antibody also showed increase in CAPE-treated cells (Fig. 2-2C), 
supported by increase detected by Western blotting (Fig.2-2D). I also examined the 
expression of endogenous HIF-1a protein in control and CAPE-treated cells, and found 
that it was increased in CAPE-treated cells (Fig.2-2E). CoCl2-treated cells were used as 
positive control (Fig. 2-2E).   
 
2.3.2 Prohypoxic doses of CAPE and its anticancer potential   
Anticancer potential of CAPE has been well documented in several studies (23;25-28). 
In view of the above findings on prohypoxia activity of CAPE, I next investigated the 
effect of low dose of CAPE on cell survival and migration. Cells treated with low doses 
(5-10 µM) showed only a minor toxicity in 48 h treatment as detected by MTT assay 
(Fig. 2-3A). I also examined the effect of CAPE on cell migration by Wound-scratch 
assays and found that low doses of CAPE failed to affect cell migration (Fig. 2-3B). 
The observation thus made was consistent with other results where no change was 
observed in protein markers of cell migration studied in control and CAPE (low non-
toxic dose)-treated cells (Fig. 2-3C).  
 
2.3.3 Pro-hypoxia doses of CAPE and protein de-aggregation  
Accurate protein folding determines their subcellular niche and functional 
characteristics (29).  Environmental conditions such as adverse temperature, pH, 
metals and oxidative stress have been established as the prominent factors leading to 
protein mis-folding and aggregation that are toxic for cells and have been associated 
with diseases including diabetes, neurodegenerative disorders, and cancer (30-33). 
Endoplasmic Reticulum (ER) plays an essential role in protein quality control by 
activating Unfolded Protein Response (UPR) in response to altered conditions of 
nutrients and oxygen that trigger protein misfolding (34). Activated UPR regulates 
expression of several pro-survival proteins (35). Interestingly, lower doses of CAPE as 
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well as mild hypoxia have been shown to activate UPR  (35;36). Several studies have 
shown that HIF-1a stabilization provides stress protection in various neurological 
disease models e.g. stroke (37;38), Parkinson’s disease (39), oxidative stress (40), 
Alzheimer’s disease (39;41;42) and mitochondrial dysfunction (43). The beneficial 
effects of HIF-1a stabilization arise mainly through the activation of HIF-1 target genes 
that combat oxidative stress, improve glucose metabolism and block cell death 
pathways (44). 
In view of this, I recruited metal (sodium arsenite) and high temperature-induced 
protein aggregation in cells exogenously transfected with either GFP or luciferase 
proteins that allowed direct readout of protein aggregation.  As shown in Fig. 2-4A, 
GFP-labelled cells were treated with sodium arsenite (24 h) followed by recovery (48 
h) either in the control or CAPE-supplemented medium.  As expected, I found that the 
cells possessed pancytoplasmic fluorescence of mortalin-GFP protein (Fig. 2-4B).  Of 
note, whereas sodium arsenate-treated cells recovered in normal medium still showed 
strong aggregation (Fig. 2-4B), protein de-aggregation was seen in the cells recovered 
in CAPE supplemented medium (Fig. 2-4B).  Consistently, I found that the sodium 
arsenite stressed cells treated with CAPE led to 20-30% increase in viability (Fig. 2-
4C). We, next, confirmed protein de-aggregation and anti-stress effect of CAPE by 
using heat shock-induced protein misfolding and aggregation of luciferase reporter 
(Fig. 2-5A) (45). As shown in Figure 8B, heat-induced aggregation of luciferase led to 
decrease in its activity.  Cells recovered in normal medium for 48 h showed reversal 
of misfolding (46), and was associated with increase in luciferase activity.  Of note, 
recovery in CAPE-supplemented medium caused 2-fold increase in luciferase activity.  
The results were confirmed by immunostaining of luciferase by specific antibodies 
(Fig. 2-5B). These data demonstrated that the prohypoxic doses of CAPE protected 
cells against stress-induced aggregation of proteins.  
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Fig. 2-1 Screening for hypoxia modulating drugs. (A) Schematic diagram showing the 
screening assay protocol for hypoxia modulating drugs. (B) HIF-1α driven Luciferase 
assay for U2OS cells stably transfected with HRE-luciferase plasmid. (C) HIF-reporter 
assay in cells treated with natural drugs (5.0 µM). Out of the 60 drugs tested, 5 
compounds (shown by dark bars) showed strong prohypoxia activity; 4 compounds 
(shown by white bars) showed anti-hypoxia activity. (D) Structure of CAPE (Obtained 
from PubChem) 
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Fig. 2-2 HIF-1α driven prohypoxia effect of CAPE on U2OS. (A) Effect of CAPE on 
HIF-1α driven luciferase reporter assays in comparison to a standard hypoxia inducing 
drug, CoCl2. (B, C and D) Effect of CAPE on the luciferase transcript (B) and protein 
as detected by immunostaining (C) and Western blotting with anti-luciferase specific 
antibody (D).  Effect of CAPE on the Luciferase protein and protein (C). Effect of 
CAPE on endogenous HIF-1α protein; CoCl2 was used as positive control.  
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Fig. 2-3 Effect of CAPE at low doses on U2OS cell viability (A), migration (B) and  
proteins (C) involved in cell migration. 
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Fig. 2-4 Effect of CAPE at low doses 
(15 µM)on sodium arsenate-induced 
aggregation in U2OS-mot-GFP and 
cell survival in U2OS cell lines. (A) 
Schematic diagram showing the 
protein aggregation and recovery assay, 
(B) aggregation of GFP in sodium 
arsenate-treated and recovered (either 
in control or  CAPE-supplemented 
medium) and (C) viability of cells treated with sodium arsenate followed by recovery 
either in control or CAPE-supplemented medium. 
	 50 
 
 
 
 
Fig. 2-5 Effect of CAPE at low doses on heat shock-induced aggregation of luciferase 
reporter and activity in U2OS. (A) Schematic diagram showing the protein aggregation 
and recovery assay, (B) luciferase activity and expression in sodium arsenate-treated 
and recovered either in control or  CAPE-supplemented medium is shown. 
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Chapter 3  
Identification of CAPE (C-021) as anti-mortalin 
molecule and studied its effect on drug resistance. 
 
3.1 Introduction 
Chemoresistance and radioresistance in cancer cells and non-selectivity of chemical 
drugs towards normal cells are the major reasons of treatment failure.  Several 
epidemiological studies have observed that the daily meal of fruits and vegetables lower 
cancer risk.  Several natural plant-derived polyphenols including curcumin, genistein, 
silymarin, caffeic acid phenethyl ester, resveratrol, green tea polyphenols, flavopiridol, 
emodin and piperine have been investigated for their chemo-therapeutic and chemo-
preventive properties and for sensitization of tumor cells to chemo- and radio-
therapeutic agents (1-7).  Looking at, availability and economic aspects, natural 
chemicals are gaining increasing focus in disease research because of their cancer-
preventive and -curative activities, and their mechanism(s) of action. A minority of 
cancer cell population, called cancer stem cells (CSC), with CD44(+/high)CD24(-/low) 
signature, has been identified in a large variety of cancers.  These cells have been 
ascribed as the key determinants of malignant transformation, metastasis and multi-
drug resistance characteristics that form a prime cause of failure in cancer 
chemotherapy leading to fatality (8-10).  CSC are also distinguished by enriched 
expression of several other markers referred to as stemness factors.  These include 
aldehyde dehydrogenase, ATP-binding cassette transporter protein-ABCG2/BCRP1, 5-
transmembrane glycoprotein-CD133, and transcriptional factor Oct-4 (11-16).  
Tumor progression, especially in case of solid tumors, is often accompanied by 
generation of hypoxia microenvironment that in turns promotes proliferation, EMT, 
invasion and metastasis (17;18).  It has been shown that cancer cells survive during 
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hypoxia by up-regulation of stemness factors (18).  Furthermore, CSC-enriched tumors 
have been shown to display chemoresistance and poor prognosis, indicating that these 
cells are an important target for therapeutic success (19;20).  In view of these reports, 
research on CSC biology is deemed important for understanding the process of 
tumorigenesis, tumor progression, treatment, prognosis and recurrence. 
Cancer cells depend heavily on mitochondria, a key organelle for regulation of 
metabolism, survival and death signalings (21).  Mortalin/mthsp70, a member of 
Hsp70 family, has been shown to promote proliferation, metastasis and angiogenesis, 
and downregulate apoptotic signaling.  It has been shown to interact with p53, 
telomerase and hnRNP-K in cancer cells (22-28). Whereas p53 is inactivated by 
mortalin in cancer cells, telomerase and hnRNP-K are activated and were shown to 
contribute to malignant transformation (29).  Mortalin was shown to inhibit p53-BAX 
interactions and activate AKT that are required for apoptotic signaling (25;30;31).  It 
was also shown to interact with complement C9, a major component of membrane 
attack complexes that are released in membrane vesicles from complement attacked 
cells accounting for resistance of cancer cells to complement-dependent cytotoxicity 
(32). Increased mortalin expression was shown to mediate resistance of ovarian cancer 
cells to cisplatin (33).  Based on these data and our recent findings on role of mortalin 
in EMT, I hypothesized that it may also be involved in cancer cell stemness.  I 
therefore investigated several cell stemness markers and drug resistance in mortalin 
overexpressing breast cancer cells.  I demonstrate that mortalin overexpressing cells 
were enriched with stemness markers and exhibit resistance to cytotoxicity induced by 
several chemotherapeutic drugs.  Furthermore, treatment of the cells with mortalin 
shRNA or inhibitors like CAPE (C-021) reverted the drug resistance of cells and 
dampened their migration and invasion potentials.    
Propolis is a natural mixture produced by honeybees by mixing plant materials with 
wax and resin to build their hives.  In ancient medicines, it has been used for anti-
bacterial, anti-inflammatory, wound healing, skin infections, gastro-intestinal disorders, 
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immunomodulation and cardiovascular benefits.  CAPE (Caffeic Acid Phenethyl 
Ester) is an active phenolic component derived from propolis.  It was known for 
several activities, previously detected in propolis, including anti-mitogenic and 
anticancer natural drug (34;35).  Several studies suggested that CAPE and its 
derivative compounds contain selective toxicity to transformed/cancer cells (36-42).  
CAPE- and Artepillin C (ARC)-rich propolis extracts were demonstrated as natural 
anti-PAK1 inhibitors and NF1/NF2 remedies (43;44). CAPE was shown to inhibit TPA 
(12-O-tetradecanoylphorbol-13-acetate)-induced tumors (45;46), and suggested as an 
anticancer agent for treatment of colorectal carcinoma (47), hepatoma (48) and gastric 
carcinoma (49). CAPE-induced cell cycle arrest and apoptosis are mediated by down-
regulation of beta-catenin (50;51) and p38MAPK (52) signaling pathways.  It was 
demonstrated to inhibit NF-kappaB, COX-2 (53;54) levels and stimulate human anti-
oxidative response element-mediated gene expression of the NAD(P) H:quinone 
oxidoreductase (NQO1) gene (55).  CAPE was reported for (i) restoring intercellular 
communication through gap junctions, regulation of phosphorylation of connexin 43 
(54), (ii) helps in rearrangement of actin cytoskeleton and loss of focal adhesion plaques 
causing reduced cell invasion (56).  It inhibited growth of cancer cells on soft agar 
through downregulation of p21ras protein (57).  Together with the in vitro reports, 
anticancer activity of CAPE was supported by in vivo studies in mice (58-60).  CAPE 
and its derivative, were shown to inhibit PI3-K/Akt, AMPK and m-TOR signaling 
cascades both in vitro and in vivo (60).  Although such reports present CAPE as a 
natural drug for cancer treatment but molecular studies are warranted to clarify and 
clarity to its mechanism of action and rational designing of its derivatives.    
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3.2 Material and methods 
3.2.1 Cell culture and reagents 
 Human normal cells (TIG-3 and MRC5) and Cancer cell lines, breast cancer (MDA-
MB 231, MCF-7), osteosarcoma (U2OS, Saos-2), cervical carcinoma (HeLa), 
hepatocellular carcinoma (HUH-6, HUH-7), ovarian carcinoma (SKOV3), 
adenocarcinoma (A549) and colorectal adenocarcinoma (DLD-1, COLO 320 and 
HCT116), procured from JCRB or DS Pharma, Japan, were cultured in DMEM (Life 
technologies). Human melanoma (G361)(JCRB, Japan) was cultured in McCoy’s 5A 
(Life technologies).  Mortalin overexpressing cells were generated by retroviral 
expression vector as described previously(61;62). Mortalin-targeting adeno-oncolytic 
virus expressing mortalin shRNA (#009-GAATGA GGCTAGACCTTTA) was 
generated and used as described earlier (63). Plasmid based mot-shRNA 2166 (5′-
ACCATCTCGCACACAGCAATTCAAGAGATTGCTGTGTGCGAGATGGTT-3’) 
was constructed and used as described earlier (24). Chemotherapeutic drugs were 
purchased from Sigma (Nocodazole, Paclitaxel, Doxorubicin hydrochloride, 
Cyclophamide monohydrate) or Wako (Methotrexate, Epirubicin hydrochloride and 
Docetaxel).  Anti-mortalin antibodies (polyclonal and monoclonal) were raised in our 
laboratory. Mortalin targeting shRNA and adeno-oncolytic viruses were generated as 
described earlier (63). 
 
3.2.2 Cell proliferation assay   
Cytotoxicity and cell survival were assessed using MTT {3-(4,5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide (Life Technologies) assays in which the cell viability 
was estimated by the conversion of yellow MTT by mitochondrial dehydrogenases of 
living cells to purple formazon (MTT assay).  Statistical significance of results was 
determined from 3-4 independent experiments including triplet or quadruplet sets in 
each experiment. 
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3.2.3 Cell migration and invasion assay 
  Cells migration and invasion assays were performed using Transwell chamber 
(Corning, NY) and BD BioCoat Matrigel Invasion Chamber (BD Bioscience, MA), 
respectively, as described earlier (62).  
 
3.2.4 Western blotting 
 Cells were cultured in DMEM (5% fetal bovine serum) in 100-mm plates and lysed 
using 1% Nonidet P-40 buffer containing a protease inhibitor cocktail (Sigma Aldrich). 
The protein concentrations of whole cell lysate were measured by bicinchonic acid 
assay (BCA) (Thermo Fisher Scientific, Rockford, IL). The cell lysates (10-20 ng) were 
separated in 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, 
MA).  Blocked membranes were probed with target protein-specific primary 
antibodies, ABCG2 (Novus Biologicals, Littleton, CO) and OCT4 (Cell signaling, 
Beverly, MA), CD24 (Santa Cruz Biotechnology INC. CA, United States), Anti-
Calreticulin (Abcam, Cambridge UK) overnight at 4°C. overnight at 4°C. The blots 
were incubated with the following secondary antibodies conjugated to horseradish 
peroxidase: anti-rabbit IgG and anti-mouse IgG (Cell signaling technology) and 
developed by enhanced chemiluminescence reaction (ECL) (Elpis Biotech, Daejeon, 
Korea). 
 
3.2.5 Immunofluorescence staining 
Cells were fixed on a glass coverslip placed in a 12 well culture dish with 4% 
paraformaldehyde in PBS, permeabilized with 0.1% Triton X-100 for 10mins, blocked 
with 0.2% BSA/PBS for 1 h and were then incubated with specific antibody (as 
described above) for overnight at 40C. For mito-tracker staining MitoTracker®Red 
CMXRos (Invitrogen, M7512) were added into the cell culture media at final 
concentration of 50nM. The cells were incubated under normal culture condition for 20 
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mins then visualized by Carl Zeiss microscope (Axiovert 200 M, Tokyo, Japan). 
Counter staining was performed with Hoechst 33342 (Sigma) for 10 mins in dark.  To 
examine the localization and sections of cells z-stack has been acquired with laser 
scanning confocal microscopy (Zeiss LSM 700). The files were transferred o a graphic 
workstation and analyzed with IMARIS software (Bitplane, Zurich, Switzerland).  
 
3.2.6 Flow cytometric analysis 
 For the assessment of cancer stem cell maker expression, cells were collected and 
suspended at a density of 1x106 cells/ml.  The cells were stained with fluorescein 
isothiocyanate (FITC)-conjugated anti-CD24, allophycocyanin (APC)-conjugated anti-
CD44, or phycoerythrin (PE)-conjugated anti-CD19 following the manufacturer's 
instructions.  Cells were incubated at 4oC for 1h followed by washings (twice) with 
PBS and analysis using a flow-cytometer (FACS Caliber, Becton Dickinson).  
 
3.2.7 Mammosphere formation assay 
For mammosphere formation, cells were plated onto 6-well plates at a density of 1x103 
cells/ml in DMEM/F-12 (Hyclone, Logan, UT) supplemented with 2% B27 (Gibco, 
Carlsbad, CA), 10 ng/ml EGF, and 10 ng/ml FGF (ProSpec,East Brunswick, NJ). 
Growth factors were added to the mammosphere cultures every 3 days, and 
mammospheres (> 40 ㎛ in size) were counted on Day 7.  
 
3.2.8 RNA isolation and cDNA synthesis 
 Total RNA was extracted from MDA-MB231, U2OS and G361 cells and their 
mortalin-overexpressing variants using TRIzol Reagent (Life Technologies) following 
supplier-described protocol. Quality and quantity were determined by 
spectrophotometery (Nano Drop, 1000 spectrophotometer).   For cDNA synthesis, 
total RNA (1 µg) was reverse-transcribed into cDNA using Quantitect Reverse 
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Transcriptase Kit (QIAGEN) following the manufacture’s protocol.  cDNA was 
stored at -20oC for PCR. 
 
3.2.9 Quantitative real-time RT-PCR 
 Gene expression was quantified by quantitative real time PCR using Syber Select 
Master mix (Applied Biosystem, Life Technologies), gene specific primers (Table 1) 
and EcoTM Real-Time PCR System (Illumina, San Diego, CA) wherein the relative 
level of expression of target gene was normalized against the internal control 18S by 
∆CT method.  An amplification plot between fluorescence signals vs. cycle number 
was plotted. The difference between the mean values in the triplicated samples of 
targeted genes and internal control 18S ere calculated by Microsoft excel and the 
relative quantitative value was expressed as 2-∆CT.  All the experiments were 
performed, at least thrice, for statistical significance. 
 
3.2.10 Metabolic rate assay  
MCF-7 and their mortalin overexpressing derivatives were suspended in serum-free, 
phenol red-free and glucose-free RPMI-1640 medium containing antibiotics and 
glutamine (4 mM). Cells were dispensed into PM-M1 microplates (2,500 cells/50 µL 
per well) and incubated for 24 -72h followed by addition of Redox Dye Mix MA (10 
µL). Plates were sealed with tape (LMT-SEAL-EX, Phenix Research Products, 
Hayward, CA) to prevent CO2 loss, and incubated at 37°C in an OmniLog instrument 
(Biolog, Hayward, CA) for 18-36 hours to obtain kinetic record (X-axis- time and the 
Y-axis-OmniLog color density units) of formazan as per manufacturer’s instructions.  
 
3.2.11 Statistical analysis 
 All the experiments were performed in triplicate. Data are expressed as mean ±SEM 
of triplicate experiments.  Unpaired t-test (GraphPad Prism GraphPad Software, San 
Diego, CA) has been performed to determine the degree of significance between the 
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control and experimental samples. Statistical significance was defined as p-value 
proliferation (green boxes), cell stasi*<0.05, **<0.01, ***<0.001 while no mark 
denotes insignificant correlation. 
 
3.3 Results and Discussion 
3.3.1 Anticancer and anti-metastasis potential of CAPE 
I examined the toxicity effect of CAPE in a variety of human cancer cell lines including 
HT1080, U2OS, MCF-7, MDA-MB-231 and G361 and found that it induces apoptosis 
in all cell types at doses higher than 10-20 µM. (Fig. 3-1A). Low doses (5-10 µM) were 
observed to cause growth arrest.  The data was consistent with other reports on 
anticancer activity of CAPE.  In order to determine if CAPE could also be used to treat 
aggressive and metastatic cancers, I prepared genetically isogenic breast cancer cells 
that are differed in their migration and metastasis potentials by retrovirus-mediated 
overexpression of stress chaperone mortalin (61;62).  In short- and long-term survival 
assays, I found that the CAPE caused growth arrest of parent and metastatic-derivatives 
of isogenic cells to a significant comparable level (Fig. 3-1 B&C).  Similar results 
were observed in other breast cancer cell lines suggesting that CAPE (10µM) may also 
be used for aggressive and malignant cells.  
 
3.3.2 CAPE causes induction of p53 function by targeting mortalin-p53 
interactions 
Based on the observed fact that GADD45a is a downstream effector of p53 tumor 
suppressor and it is also involved in growth arrest of cells in response to DNA damage, 
I hypothesized that CAPE-induced GADD45a could be mediated by activation of p53.  
Examination of p53 in control and CAPE-treated cells indeed revealed that p53 
upregulates and translocates into the nucleus and increase in its downstream effector 
p21WAF1 in MCF-7, U2OS as well as A549 cells (Fig. 3-2 A).  Upregulation of p53 
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and p21WAF1 in treated cells was confirmed by Western blotting (Fig. 3-2 B). In addition, 
p53-dependent reporter assays also shown increase in transcriptional activation 
function of p53 in CAPE-treated cells (Fig. 3-2 C).  The involvement of mortalin and 
p53 in complex formation was already known so, I predicted that the increase in p53 
might be due to targeting of mortalin (stress chaperone known to inhibit p53 activities) 
by CAPE. Mortalin is well known to promote carcinogenesis and metastasis signaling. 
I next checked the expression level of mortalin in control and CAPE-treated cells. As 
shown in Fig. 3-3 A-C, there was a decrease in mortalin at both protein and transcript 
level in CAPE-treated cells.   I examined the expression level of other cell migration 
regulators in these cells and found decrease in vimentin, MMP-2, MMP-3, b-catenin, 
TGF-b and WNT-3a transcripts (Figs. 3-3 C&D). Of note, CAPE-gCD performed 
better and showed higher decrease (Fig. 3-3 A).  
 
3.3.3 Mortalin overexpressing cells possess higher level of expression of cancer cell 
stemness markers 
 Mortalin is enriched in a large variety of cancer cells (61;64-68). In this study, I first 
investigated the expression level of mortalin and CD24 in parallel in some normal, 
immortalized and tumor derived cells (Fig. 3-9 A).  As expected, mortalin was 
upregulated in all cancer cell lines examined as compared to the normal cells. 
Interestingly, CD24 expression showed variability. Whereas SV40- immortalized 
(JFCF-6B and 4D) and several tumor-derived cells (MCF-7, G361, SKOV3, HUH-6, 
A549, DLD1, COLO 320, HCT 116) showed increase in CD24 expression as compared 
to the control cells, others (MDA-MB 231, Saos-2, HeLa, HUH-7, H1299) (Fig. 3-9 A) 
showed decrease. Based on these data, I selected breast adenocarcinoma MDA-MB 231 
(low level of CD24) and MCF-7 (high level of CD24) for the current study and 
determined the role of mortalin by generating their overexpressing derivatives. In order 
to examine the role of mortalin in cancer cell stemness characteristics, I first 
investigated the expression of two major stem cell markers, ABCG2 and OCT4 in 
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control and their mortalin-overexpressing derivatives (Mot-OE) by Western blotting 
with specific antibodies.  As shown in Fig. 3-4 A, Mot-OE MCF-7 cells possessed 
higher expression of both ABCG2 and OCT4 as compared to the control and, showed 
high efficacy of spheroid formation (Fig. 3-4 B).  Consistent with these, Mot-OE cells 
exhibited CD44high/+ (97.3%) and CD24low/- (17.0%) level of expression as compared to 
the parent MCF-7 cells (Fig. 3-4 C).  The results were also validated by qPCR that 
confirmed higher level of expression of CD9, MRP1, CD133 and ALDH1 (Fig. 3-4 D) 
in Mot-OE as compared to the control cells.  Furthermore, mortalin overexpression 
caused decrease in CD61 and CD24 expression at the transcription level (Fig. 1D).  
Mortalin-overexpressing MDA-MB 231 cells also showed higher level of expression 
of CD9 and lower level expression of CD24 and CD61 as compared to the control 
parental cells (Fig. 3-5 A).  These cells also showed high spheroid-forming capability, 
about 10-fold higher expression of cancer stem cell marker, CK19 (Fig. 3-5 B) and 
significant upregulation of ABCG2 and OCT4.   Similar results were obtained in 
U2OS (Fig. 3-5 B) and G361 cells (Fig. 3-5 C) showing that mortalin upregulation 
enhances the cancer stem cell characteristics as determined by upregulation of ABCG2, 
MRP1, CD133, and downregulation of CD61 and CD24.  
Examination of cell migration characteristics of control and Mot-OE cells revealed that 
MCF-7/mot-OE cells possess higher migration and invasion ability and was consistent 
with the earlier findings22. Furthermore, both migration and invasion were 
compromised in cells treated with mortalin-shRNA cells as compared to the respective 
controls. Similar results were also obtained for MDA-MB 231 cells (68).  Taken 
together, these data suggested that upregulation of mortalin overexpression in cancer 
cells contributes to cancer cell stemness in a cell line-unspecific manner. 
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3.3.4 Mortalin contributes to drug-resistance in cancer cells and offers a target for 
better cancer therapy 
Since resistance of cancer stem cells to chemotherapeutic drugs is one of their major 
characteristics that possess a foremost hurdle to cancer treatment, I next investigated if 
mortalin overexpression contributes to drug resistance of cancer stem cells.  As shown 
in Fig. 3-6 A&B, mortalin-overexpressing derivatives of both MDA-MB 231 and MCF-
7 cells showed resistance to several anti-cancer drugs.  Of note, mortalin-knockdown 
using shRNA plasmid sensitized the cells to the drugs (Fig. 3-6 C).  In order to further 
validate these findings, I recruited mortalin-targeting adeno-oncolytic virus (harboring 
independent mortalin targeting site as described in material and methods section) that 
was shown to cause mortalin knock-down and tumor suppression in vitro and in vivo 
(63).  Cells treated with subtoxic doses of mortalin-targeting adeno-oncolytic virus, as 
described earlier (63;68), showed better drug response. In line with this data, (33) have 
also reported that elevated levels of mortalin expression were responsible for resistance 
of ovarian cancer cells to cisplatin (33).   
In light of above data, I next used mortalin inhibitors MKT-077 (a cationic 
rhodacyanine dye) (69;70) (24;71) and CAPE (Caffeic Acid Phenethyl Ester, a 
bioactive compound in honey bee propolis) (72) to sensitize cancer cells to various 
drugs.  Since MKT-077, CAPE and other drugs used in this study could cause cancer 
cell apoptosis by themselves, their subtoxic doses (as determined by independent 
experiments) were used in order to avoid their cytotoxic effect per se, and to achieve 
knockdown of mortalin as reported earlier (24;69-71).  As shown in Fig. 3-10 A, I 
found that pretreatment of MCF-7 cells with sub-toxic dose of MKT-077 (0.2~0.5 µM), 
sensitized them to various chemotherapeutic drugs) (Table 2).  CAPE (0.8 µM) that 
was seen to cause reduction in mortalin expression both at the transcriptional and 
translational level (Fig. 3-10 A&B) also caused similar sensitization of cancer cells to 
a variety of drugs (Fig. 3-10 B).  Similar results were obtained in MDA-MB 231 and 
	 68 
U2OS cells (Fig. 3-10 c-f) suggesting that targeting of mortalin by shRNA or small 
molecules including natural drugs potentiated the effect of anticancer drugs.  
Mortalin has been shown to play key role in mitochondria biogenesis (28). It has been 
identified as the only ATPase component of the mitochondrial import complex and is 
essential for the translocation of most mitochondrial inner membrane and matrix 
proteins. It binds to Tim44 (inner mitochondrial membrane translocase) and serves as 
the ATP-driven force generating motor during protein import (73-75). Mortalin 
depletion altered mitochondrial bioenergetics, depolarized mitochondrial membrane, 
decreases oxygen consumption and extracellular acidification and increased oxidative 
stress in medullary thyroid carcinoma cells (76). I have earlier detected expression of 
retrovirally-expressed mortalin in mitochondria (62), and hence the mitochondrial 
functions of upregulated mortalin may contribute to increasing metabolic demand that 
accompanies increased proliferation capacity of cancer stem cells. Glucose uptake, 
ATP content, OCR and membrane potential are higher in CSC as compared to non-
CSC. Analysis of metabolic curves of MCF-7 and their mortalin overexpressing 
derivatives by real time automated kinetic cell assays (OMNILOG) confirmed the 
higher metabolic rate of mortalin overexpressing derivatives (Fig. 3-9 B).  
Mitochondria has been implicated in cell stemness and differentiation properties (77) 
(78) (79) also due to its key role in cellular oxygen consumption and extracellular 
acidification characteristics. Mortalin, Hsp60 and several other mitochondrial proteins 
have been shown to be essential regulators of oxidative stress (28;29;80-83). Role of 
mortalin in protection against oxidative stress was also confirmed in Alzheimer disease 
model where suppression in mortalin expression significantly increased mitochondrial 
membrane depolarization and reduced the cellular ATP levels in neuroblastoma cells 
(84).  It was shown to regulate hematopoietic stem cell function by controlling 
oxidative stress (80;85).   In light with these reports, increased mortalin expression in 
cancer cells was predicted to increase (i) mitochondrial potential resulting in lower ROS 
	 69 
level, (ii) oxygen consumption in hypoxia condition, cellular ATP levels and (iii) 
maintain cancer stemness and drug resistance properties. 
A variety of stressful environmental conditions induce heat shock proteins.  Cancer, a 
physiologically stressed conditions that challenge cell survival in limited nutirents and 
oxygen supply, has been associated with upregulation of heat shock proteins (Hsp) 
including mortalin, Hsp70, Hsp90 and Hsp27.  These have been predicted to hold 
diagnostic and prognostic clinical applications (86-88) and hence warranted studies.  
Multifunctional stress chaperone mortalin, enriched in cancers and found in various 
subcellular sites (the mitochondrion, plasma membrane, endoplasmic reticulum, 
cytosol and nucleus) has been shown to interact with tumor suppressor protein-p53, 
inactivates its transcriptional activation and apoptotic functions in cancer cells resulting 
in activation of proproliferation signaling (24-26;77;89-91).  Nuclear mortalin has been  
shown to promote cancer cell metastasis by mechanism involving functional activation 
of telomerase and heterogeneous ribonucleoprotein K (hnRNP-K)(62).  Role of 
mortalin in cancer cell stemness has not been elucidated and hence warrated 
investigations.  I found that core markers of cancer cell stemness (i) ABCG2, the ATP-
binding cassette transporter protein that reduces the intracellular concentration of drugs 
and (ii) Oct-4 transcriptional factor that is critically involved in the self-renewal and 
drug resistance (11-16) were upregulated in mortalin-overexpressing cells.  
Furthermore, stem cell surface markers proteins, CD133, MRP1, ALDH1, CD9 also 
showed increase in mortalin overexpressing cells.  In light of these information and 
data, I next considered if the anti-mortalin small molecules MKT-077 and CAPE 
affected a specific pool of subcellular mortalin.  MKT-077 has been reported to cause 
significant decrease in mortalin levels leading to short/compressed/fragmented 
mitochondria (32;69;76;92-94). It was also shown to abrogate mortalin-p53 interactions, 
causing nuclear translocation and reactivation of p53 in cancer cells (24;25;69;71). (32) 
have also shown Mortalin-MAC (Membrane Attack Complex) complexes are released 
in membrane vesicles from complement attacked cells causing resistance of cancer cells 
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to complement-dependent cytotoxicity (32).    siRNA-mediated knock down of 
mortalin or MKT-077 reduced MAC elimination and resulted in enhanced cell 
sensitivity to MAC-induced cell death.  
I examined effect of CAPE on mortalin by expression and dual-immunocytostaining 
assays. As shown in Figs. 3-7 A-D,  CAPE treated cells showed decrease in level of 
expression at mRNA as well as protein level, decrease in intensity and shift of mortalin 
staining from perinuclear to pancytoplasmic type. Furthermore, decrease in mortalin 
was clearly observed in the cell nucleus by analysis of the images by IMARIS software 
(Fig. 3-7 D). Dual co-immunostaining of mortalin and ER resident protein calreticulin 
in control and CAPE treated cells revealed that although high doses of CAPE caused 
decrease in both proteins, the low doses were more effective to mortalin (Fig. 3-8 A).  
Similar analysis with hnRNP-K revealed significant decrease in mortalin in the nucleus 
of CAPE treated cells (Figs. 3-8 B&C). Taken together, it was concluded that targeting 
of mortalin by subtoxic doses of CAPE caused drug sensitization by multiple ways 
including its functions in mitochondria, ER and nucleus (28); nuclear clearing seemed 
most remarkable of all.  Of note, nuclear mortalin has been assigned roles in EMT and 
malignant transformation (62;68). Other drugs that have been shown to target mortalin 
or its functions include Withanone, Withaferin-A and Embelin that caused activation 
of Tumor Suppressor protein p53 and deactivation of metastatic signaling in cancer 
cells (95-97), and veratridine that sensitized cancer cells to chemotherapeutic drugs by 
UBXN2A-dependent inhibition of mortalin (98).         
The most effective chemotherapeutic agents in breast cancer are doxorubicin, taxol, 
cyclophosphamide, methotrexate, 5-fluorouracil and their combination chemotherapy 
program.   Although each of these drugs possesses appreciable tumor regression and 
anti-metastatic properties, they are often complicated drug-resistant cancer cell sub-
population (CSCs) responsible for tumor relapse.  Vargas-Roig et al. reported 
increased level of nuclear Hsp70 in the clinical samples of breast cancer that showed 
with drug resistance to doxorubicin, cyclophosphamide, methotrexate and epirubicin 
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(85).  I have earlier demonstrated that mortalin promotes malignant transformation of 
cancer cells by increasing their proliferative and migration capacity and hence mortalin 
is a promising target for cancer therapy (24-26;61-63;68;89).   In the present study, I 
report that the CSC cells have high expression of mortalin that contributes to their 
stemness and drug resistance characteristics. In recent studies, I have also shown that 
like CAPE, Artepillin C a brazillian propolis major component also interfere in p53-
mortalin complex (99).  I demonstrate that anti-mortalin drugs, CAPE and MKT-077, 
reverted the drug resistance and hence could be useful new adjuvants for increasing the 
efficacy and outcome of chemotherapy. 
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Fig. 3-1 Cytotoxicity of CAPE to human cancer cells.  Dose dependent loss in cell 
viability in cells treated with CAPE is shown.  IC50 for A549, HT1080, G361 and 
U20S were ~100, 5, 20, 60 µM respectively (A).  Effect of CAPE on cell viability (B) 
and colony forming efficiency (C) of MCF-7, MDA-MB-231 cells and their mortalin-
overexpressing metastatic deriatives showing that CAPE (10µM) inhibited cell 
proliferation in both short term (A) and long term (B) viability assays. 
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Fig. 3-2 Activation of p53-p21 pathway by CAPE.  (A) Immunostaining of p53 and 
p21 in control and CAPE (5µM) treated cells showing their increase.  (B) Increase in 
p53 and p21 as determined by Western blotting with specific antibodies.  (C) p53-
dependent reporter assay showing increase in transcriptional activation function of p53 
in CAPE-treated (5µM) than in control cells. 
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Fig-3-3 Downregulation of mortalin and other metastasis-regulatory proteins by CAPE.   
Effect of CAPE on mortalin and cell migration regulatory proteins. Decrease in 
mortalin, vimentin, MMP-2 was obserevd by Western blotting (A),  immunostaining 
(B) and RT-PCR (C).   Decrease in mortalin, vimentin, b-catenin, TGF-b and Wnt-
3a as determined by qPCR is shown (D) 
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Fig. 3-4 Mortalin overexpressing MCF-7 cells showed higher expression of cancer stem 
cell marker proteins ABCG2, OCT4 as determined by Western blotting (A) and showed 
high degree of spheroid formation (B).  FACS and RT-qPCR analysis revealed higher 
level of expression of CD44 (C), CD9, MRP1, CD133 and ALDH1 (D) and low level 
of expression of CD24 (C and D), CD61 (D) in mortalin-overexpressing as compared 
to the control cells.  
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Fig. 3-5 Mortalin overexpressing MDA-MB 231 cells showed low level of expression 
of CD24, CD61 and high level of expression of CD9 as compared to the control cells 
(A).  Mortalin overexpressing U2OS cells showed low level of expression of CD61 
and high level of expression of ABCG2, MRP1, CD133, & Connexein as compared to 
the control cells (B) Mortalin overexpressing G361 cells showed high level of 
expression of CD9, MRP1, CD133 and ALDH1 (C). 
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Fig. 3-6 Mortalin overexpressing MDA-MB 231 (A) and MCF-7 (B) cells showed 
higher viability when treated with a variety of drugs indicating drug resistance 
characteristics.  Knockdown of mortalin with shRNA caused sensitization to the drugs 
(C). 
 
 
 
	 78 
 
 
 
 
 
 
 
Fig. 3-7 MCF-7 & MDA-MB 231 cells treated with CAPE showed downregulation of 
mortalin mRNA (A) and protein (B) as compared to the control cells. Dual 
immunostaining of control and CAPE treated cells with mortalin antibody and mito-
tracker showed decrease in mortalin intensity (C). IMARIS analysis of images showed 
remarkable reduction in nuclear mortalin, shown by white arrows (D). 
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Fig. 3-8 CAPE treated MDA-MB 231 cells showed downregulation of mortalin & 
calreticulin. Dose response analyses showed stronger effect on mortalin than 
calreticulin (A).  Coimmunostaining of mortain and nuclear protein hnRNP-K showed 
reduction in mortalin and its remarkable clearance from the nucleus (B) IMARIS 
images of control and CAPE treated cells showing reduction in nuclear mortalin, shown 
by white arrows (D) 
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Fig. 3-9 Quantitation of the protein signals obtained by Western blotting with specific 
anti-mortalin and anti-CD24 antibodies is shown. The expression was normalized 
against endogenous protein, b-actin as a loading control (A).  Real time metabolic 
rate of control and mortalin overexpressing MCF-7 cells as determined by Omnilog 
incubator (B). 
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Fig. 3-10 MCF-7 (A) and MDA-MB231 (B) and U2OS (C) cells when treated with 
mortalin inhibitors (MKT-077 or CAPE) showed better response to a variety of 
anticancer drugs. 
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Table 1. Sequence of primers used for real time PCR analysis. 
ABCG2 Forward 5′-TTCTCCATTCATCAGCCTCG-3′ 
 Reverse 5′-TGGTTGGTCGTCAGGAAGA-3′  
CD61 Forward 5’-ATGGGACACAGCCAACAACC-3’ 
 Reverse 5’-GTGGCACAGGCTGATAATGA-3’ 
CD-133 Forward 5’-GCATTGGCATCTTCTATGGTT-3’ 
 Reverse 5’-CGCCTTGTCCTTGGTAGTGT-3’ 
MRP1 Forward 5’-TCTGGGACTGGAATGTCACG-3’ 
 Reverse 5’-CCAGGAATATGCCCCGACTTC-3’  
Connexin 43 Forward 5’-CTACTCAACTGCTGGAGGGAAG-3’ 
 Reverse 5’-GGCCACCTCAAAGATAGACTTG-3’  
ALDH 1 Forward 5’-CGCAAGACAGGCTTTTCAG-3’ 
 Reverse 5’-TGTATAATAGTCGCCCCCTCTC-3’ 
CD 24 Forward 5’-CCCACGCAGATTTATTCCAG-3’ 
 Reverse 5’-GACTTCCAGACGCCATTTG-3’ 
CD 9 Forward 5’-ATGATGCTGGTGGGCTTC-3’ 
 Reverse 5’-GCTCATCCTTGGTTTTCAGC-3’ 
Mortalin Forward 5’-AGC TGG AAT GGC CTT AGT CAT-3’ 
 Reverse 5’-CAG GAG TTG GTA GTA CCC AAA TC-3’ 
CD61 Forward 5’-ATGGGACACAGCCAACAACC-3’ 
 Reverse 5’-GTGGCACAGGCTGATAATGA-3’ 
HIF-1a Forward 5’-CCAGCAGACTCAAATACAAGAACC-3’ 
  Reverse 5’-TGTATGTGGGTAGGAGATGGAGAT-3’ 
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Table 2. Drug doses used for different cell lines. 
 MCF-7  
(µM) 
MDA-MB231  
(µM) 
U2OS   
(µM) 
MKT-077 / CAPE 0.5 / 10 0.4 / 20 0.6 / 15 
Nocodazole 2.0 1.0 1.0 
Paclitaxel 2.0 1.0 1.0 
Doxorubicin 0.4 0.2 0.2 
Methotrexate 2.0 1.0 1.0 
Epirubicin Hydrochloride 2.0 1.0 1.0 
Cyclophosphamide 5000 5000 5000 
Docetaxel 2.0 2.0 2.0 
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Chapter 4  
Screening of drug library by HRE driven luciferase 
reporter System-Identification of Withaferin-A (C-
024) as anti-hypoxia factor and its major role in NF-kB 
signaling.  
 
4.1 Introduction 
NFκB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) family of 
proteins is a class of transcription factors that possess a Rel homology domain in their 
N-terminus and control expression of genes involved in regulation of growth, apoptosis, 
immuno-regulatory and inflammatory processes (1;2). It regulates cellular response to 
oxidative stress, cytokines, bacterial and viral antigens and plays a key role in regulating 
the immune response to infection (3). NFκB1 and NFκB2 are transcription factors 
synthesized as large precursors, p105, and p100 that are cleaved to mature NFκBp65 
and p50 proteins by selective degradation of their C-terminal region containing ankyrin 
repeats (4).  These are present in cells in an inactive (cytoplasmically sequestered) 
state by binding to their inhibitors, called IκBs (Inhibitor of NFκB).  Intracellular or 
extracellular stresses, cytokine signals that activate its upstream regulator, IKK 
(Inhibitor of IκB Kinase), phosphorylate IκBα at Ser32 and Ser36 residues. The 
phosphorylated IκBα undergoes proteasomal degradation resulting in active NFκB that 
translocates to the nucleus and performs transcriptional activation function (5;6). The 
NFκB proteins lack intrinsic transcriptional activation ability and function by binding 
as homodimers (7).  Its crucial role in processes like proliferation, apoptosis and 
invasiveness requires controlled activation (8). Dysregulated activation has been shown 
to be associated with various conditions like arthritis, asthma and inflammatory 
disorders (1;9;10). Aberrant or constitutive activation of NFκB has been observed in 
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various types of cancer cells marking it as a potential therapeutic target (1;2;11;12).  
In line with this, identification and functional characterization on natural and synthetic 
inhibitors of NFκB have been initiated. Inhibition of NFκB by small molecules, β-
Mangostin (βM) isolated from Cratoxylum arborescens (13) and Wi-A (Withaferin-A) 
isolated from medicinal herb Withania somnifera (Ashwagandha) (10;11;14;15) has 
been reported.  It was shown that Wi-A inhibits DNA binding of NFκB resulting in 
ROS generation, mitochondrial dysfunction, oxidative stress and apoptosis in cancer 
cells (14-17). 
DNA damage response is differentially regulated in cancer and normal cells. Whereas 
normal cells respond by executing growth arrest, cancer cells are refractory and keep 
proliferating (18). Several studies have established that DNA damage response (DDR) 
signaling is essential for execution of senescence, an established powerful tumor 
suppressor mechanism (19;20). The p38MAPK is a kinase that is activated through 
environmental stress and DNA damage stress including ionizing radiation, UV, 
chemotherapeutic drugs, and lead to the induction of a G2/M cell cycle checkpoint 
through p53-dependent and independent mechanisms (21;22). p38MAPK has been 
shown to transcriptionally activate NFκB leading to senescence (23-25), mediated by 
upregulation of p53-p21WAF1 pathway. CARF (Collaborator of ARF), an ARF 
(Alternative Reading Frame, p14ARF)-interacting protein, has been shown to regulate 
activities of p53-tumor suppressor protein in an ARF-dependent or -independent 
manner (26-28). It has been shown to regulate DNA damage response in a dose 
dependent manner and regulates cell proliferative fates in normal and cancer cells 
(28;29). 
Wi-A has been shown to cause inhibition of IKK activity in some earlier studies. 
(10;15;30) Through bioinformatics analysis, I had previously shown that Wi-A disrupts 
important hydrophobic interaction between IKKβ and Nemo chain residues, L93:F734, 
T735:F92, F734:M94, W739:F97, W741:A100, W741:R101, thereby inhibiting their 
complex (31). However, an experimental study failed to reveal the inhibition of IKKβ-
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Nemo interaction by Wi-A, instead it inhibited IκB kinase activity by interacting with 
C179 residue located in catalytic domain of IKKβ (10). It was also demonstrated that 
Wi-A hyper-phosphorylates IKKβ at S181 causing inhibition of TNF-induced IKK 
activity and, thereby, causing inhibition of IκB degradation and p65 translocation (15). 
These reports described three different binding sites of Wi-A on IKK complex 
suggesting its interaction at multiple sites. Inhibition of IKK activity by Wi-A and/or 
NFκB translocation to the nucleus has been reported in some studies (10;15;30). 
However, the molecular insights and overall impact of interactions of Wi-A with IKKβ 
or NFκB structure and activity remain undefined. I provide experimental evidence to 
the activation of kinase activity of IKK complex resulting in phosphorylation of 
IkBa and nuclear translocation of NFκB. Wi-A was further seen as not disrupting 
NFκB-DNA interactions. Of note, I found that the cancer cells that showed activated 
NFκB and p38MAPK possessed decreased level of expression of cyclin D1, cyclin E 
and CDK-2/4.  I provide evidence that Wi-A trigger DNA-damage response, as 
supported by upregulation of gH2AX and CARF that yielded senescence in both cancer 
and normal cells.    
 
4.2 Material and Methods  
4.2.1 Cell culture and antibodies 
Human lung carcinoma (H1299 and A549) and normal fibroblasts (MRC5) were 
cultured in RPMI-1640 and DMEM mediums, respectively, supplemented with 10% 
(V/V) FBS (fetal bovine serum) in 5% CO2 and 95% air humidified incubator. The 
antibodies against NFκB (p65), p-IκBa p53, p38MAPK, p16INK4A, CDK2, Cyclin E, 
Cyclin D1 and Cdk-4 (Santa Cruz Biotech Inc. CA, USA) and HP1g, p-p38MAPK, pRb 
(S780), gH2AX, p21WAF1 (Cell signaling, Beverly, MA, USA) were purchased. Anti-β-
actin antibody was purchased from Abcam, Cambridge, UK.  Anti-CARF antibodies 
were generated in our laboratory. 
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4.2.2 Cell viability assay 
 The cells were seeded in 96-well tissue culture plates and treated with different 
concentrations of Wi-A for indicated time intervals followed by incubation with 0.5 
mg/ml MTT (Invitrogen, Carlsbad, CA) in media for 4 h at 37°C in CO2 incubator.  
100 µl of dimethyl sulfoxide were added to each well for cell lysis.  Absorbance (570 
nm) was measured using a microplate reader (Infinite 200 PRO; Tecan Group Ltd., 
Mannedorf, Switzerland).  All assays were performed independently, at least, three 
times. 
 
4.2.3 Colony forming assay 
H1299 cells were treated with Wi-A (0.2 µg/ml and 1 µg/ml).  After 24 h, 5 x 102 cells 
were re-plated on 6-well culture plate and observed for colonies every alternate day up 
to 10 days with regular change of medium (without drugs).  Colonies were washed 
with PBS, and fixed with a pre-chilled methanol for 10 min at 4oC followed by staining 
with 0.1% Crystal violet (Sigma-Aldrich, MO).  The stained plates were dried, 
photographed and colonies were counted.  
 
4.2.4 Western blot analysis 
The cells were treated with Wi-A (0.2 µg/ml and 1 µg/ml) for 24 h following which 
cell lysates were prepared in RIPA buffer (Thermo Scientific, Rockford, IL) containing 
complete protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany).  
Cell lysates (containing 20 µg protein) were separated on a SDS-polyacrylamide gel 
using Mini-PROTEAN® Tetra cell equipment (Bio-Rad, Hercules, CA), and 
transferred onto PVDF membrane (Millipore, Bedford, MA) by Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad).  Membranes were blocked in 0.2% Tween 
20 in TBS containing 3% BSA followed by incubation with specific antibodies (1-2 h), 
washing buffer (0.2% Tween 20 in TBS; 3x10 min) and then horseradish peroxidase-
conjugated secondary antibody (45 min), and washing buffer (3x10 min).  The blots 
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were then developed using chemiluminescence (GE Healthcare, UK) and visualized 
using Lumino Image Analyzer equipped with CCD camera (LAS3000-mini; Fuji Film, 
Tokyo, Japan). Nuclear and cytoplasmic fractions were prepared using the Qproteome 
cell compartment kit (Qiagen, Hilden, Germany). 
 
4.2.5 Immunostaining 
 Cells (1 x 104), cultured on a glass coverslips placed in a 12-well plate, were treated 
with Wi-A (0.2 and 1.0 µg/ml).  Briefly, cells were washed with cold phosphate-
buffered saline (PBS) and fixed with pre-chilled methanol: acetone (1:1) for 5 min at 
4°C.  Fixed cells were washed with PBS, permeabilized with 0.2% Triton X-100 in 
PBS and incubated in blocking buffer (2% BSA in PBS) containing anti-NFĸB (p65), 
p-IκBa, p53, p21WAF1, Cyclin E, CDK2, CDK6, p-p38MAPK, pRb (S780), gH2AX, 
HP1γ  or anti-CARF primary antibodies at 4°C overnight.  Cells were washed 
extensively in washing buffer (0.2% Triton X-100 in PBS) before incubation with the 
fluorochrome-conjugated secondary antibodies (Alexa-488-conjugated goat anti-rabbit, 
anti-mouse, Alexa-594-conjugated goat anti-rabbit or anti-mouse (Molecular Probes, 
OR)) for another 30 min.  After six washes in washing buffer, cells were overlaid with 
a coverslip with FA Mounting Fluid (VMRD Inc. Pullman, WA). The cells were 
examined on a Zeiss Axiovert 200M microscope (Carl Zeiss Microimaging, 
Thornwood, NY) and analyzed by AxioVision 4.6 software (Carl Zeiss Microimaging). 
To examine and confirm the localization of p65 in cells, z-stack had been acquired with 
laser scanning confocal microscopy (Zeiss LSM 700). The files were transferred to a 
graphic workstation and analyzed with IMARIS software (Bitplane, Zurich, 
Switzerland).  
 
4.2.6 Cell cycle analysis 
H1299 and MRC5 cells were treated with indicated doses of Wi-A for 24 h.  Cells 
were collected in 1.5 ml tube, washed with cold PBS and fixed with 70% ethanol at 4oC 
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for 12 h.  The fixed cells were centrifuged (2000 rpm for 10 min), washed with cold 
PBS twice and then re-suspended in 0.25 mL PBS.  The cells were stained with Guava 
Cell Cycle Reagent (Millipore) for 30 min in dark.  To avoid false DNA-PI staining, 
RNA was removed by adding 5 µl of 1 mg/ml RNAse A at 37oC for 1 h in cells 
suspension before PI staining.  The stained cells were applied for cycle analysis using 
Guava® PCA-96 System (Millipore) and cell cycle status was analyzed by CytoSoft 
TM Software, version 2.5.6 (Millipore). 
 
4.2.7 Apoptosis assay 
H1299 cells were seeded at a density of 2 X 105 cells/well in 6-well plates for 24 h 
followed by treatment with Wi-A. Apoptosis assay was executed using Guava Nexin 
Reagent (EMD Millipore Corporation) following the protocol recommended by the 
manufacturer. Apoptotic cells were quantitated with the help of Flow Jo Software. 
 
4.2.8 Senescence-associated β-galactosidase (SA-β-gal) assay 
 SA-β-gal detection kit (Cell Signaling Technology, Danvers, MA, USA) was used 
following manufacturer’s instructions. Cells showing blue staining were considered 
positive staining and considered as senescence cells. Three independent experiments 
were performed for data reproducibility. 
 
4.2.9 Statistical analysis 
All the experiments were performed in triplicate, independently. Variables were 
expressed as mean ±SEM of triplicate experiments.  Unpaired t-test (GraphPad Prism 
GraphPad Software, San Diego, CA) has been performed to determine the degree of 
significance between the control and experimental samples. Statistical significance was 
defined as p-value and represented by *P<0.05, **P<0.01, ***P<0.001 while no mark 
denotes insignificant correlation. 
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4.3 Results and Discussion 
4.3.1 Wi-A, at low dose, triggers growth arrest in human lung carcinoma 
Human lung cancer (H1299) cells were treated with two doses Wi-A (low, 0.2 and high, 
2.0 µg/ml).  As shown in Fig. 4-1 A, whereas high dose caused 50% reduction in 
viability within 48 h, low dose caused only ~10% reduction followed by slow growth 
arrest.  Annexin IV cytometric analysis revealed that the high, not low, dose instigated 
apoptosis in about 48 h (Fig. 4-1 B).  In contrast to 5.12% in control, 8.71% and 34.59% 
cells were detected in apoptosis in low and high dose treated cultures, respectively (Fig. 
4-1 C). Low dose-induced slow growth arrest lead to reduction in colonigenicity in 
long-term colony forming assays (Fig. 4-1 C) and most interestingly, I found that 
whereas low dose (24-48 h treatment) induced Go/G1 cell cycle arrest in H1299 cells, 
the normal (MRC5) cells remained unaffected (Fig. 4-1 D).  
 
4.3.2 Low dose of Wi-A caused nuclear translocation of NFκB in cancer cells 
I next treated H1299 (cancer) and MRC5 (normal) cells with low dose of Wi-A (0.2 to 
1.0 µg/ml) for 24-48 h and examined the localization of NFκB in control and treated 
cells. As shown in Fig. 4-2 A NFκB showed nuclear translocation only in cancer cells. 
The results were confirmed by confocal laser scanning microscopy (Fig. 4-2 B) as well 
as biochemical analyses including cell fraction and Western blotting with anti-NFkB 
antibody (Fig. 4-2 C&D). I found that the expression of NFκB (p65) was enhanced in 
Wi-A treated H1299 and A549 cells. (Fig. 4-2 C) The nuclear translocation of NFκB in 
response to treatment was also confirmed by cell fractionation and Western blotting 
analyses using with specific antibodies against cytoplasmic (lamina/C) and nuclear (a-
tubulin) proteins (Fig. 4-2 D).  The nuclear enrichment of NFκB (p65) suggested its 
activation in cancer cells, and was in contrast to the earlier reports that have predicted 
inactivation of NFκB by Wi-A (10;15). 
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4.3.3 Wi-A caused nuclear translocation of NFκB and p38MAPK 
In order to confirm the above computational findings, I performed experiments using 
human lung cancer (H1299 and A549) and normal (MRC5) cells. As shown in Fig. 4-
3A, immunostaining of control and Wi-A treated H1299 cells with anti-phosphorylated 
IκBα antibody revealed its increased level in cancer, but not in normal, cells. 
Furthermore, Wi-A induced increase in phosphorylated IκBα supporting the nuclear 
translocation of NFkB in cancer cells (Fig. 4-3A).  Several studies have shown that 
NFκB is regulated by p38MAPK, activated in response to various environmental 
stresses including DNA damage signaling, UV, ionization radiation, oxidative stress 
and cytokines (32). Activation causes its phosphorylation, essential for its nuclear 
translocation, (21) that in turn stimulates NFκB signaling (33). In view of these reports, 
I investigated whether Wi-A-induced activation of NFκB was mediated by p38MAPK.  
As shown in Fig. 4-4 A&B I found nuclear p38MAPK in cancer cells. It was confirmed 
to be in activated phosphorylated form by Western blotting with phosphorylation 
specific antibodies (Fig. 4-4 C). Normal cells did not show increase in p38MAPK (Fig. 
4-4 A). The data suggested that Wi-A preferentially instigated DNA damage response 
and activation of NFκB in cancer cells only. 
 
4.3.4 Wi-A caused upregulation of DNA damage response in cancer and normal 
cells In order to further clarify, I examined the level of CARF expression, an established 
important regulator of DNA damage response and proliferation fate of cells (26;28). As 
shown in Fig. 4-6 A&C, I found an upregulation of CARF in Wi-A treated cancer cells.  
In contrast to the activation of NFκB and p38MAPK, occurred selectively in cancer 
cells (Fig. 4-4 A and 4-6 A), the level of CARF was upregulated in normal cells in 
response to Wi-A treatment. In line with this data, both cancer and normal cells also 
showed increase in gH2AX foci (Fig. 4-6 A) and ROS (Fig. 4-6 A) consequent to Wi-
A treatment, suggesting that it may cause growth arrest/senescence both in cancer and 
	 105 
normal cells. Analyses of p21WAF1 and p16INK4A proteins that regulate growth arrest and 
senescence in cells revealed heir increase in Wi-A treated cancer and normal cells (Fig. 
4-6 C&D).  As expected, the downstream effector of these proteins CDK4 and CDK2 
showed decrease that in turn decrease the phosphorylated pRB leading to cell cycle 
arrest (Fig. 4-8 A-D). Although normal cells did not show decrease in expression of 
Cyclin D1 (Fig. 4-5 A) or CDK4 (Fig. 4-7 A&D) expression levels, phosphorylated 
pRB showed distinct decrease in Wi-A treated cells (Fig. 4-7 D) suggesting decrease in 
kinase activity of CyclinD1-CDK4 complex.  Indeed, induction of senescence was 
confirmed by b-gal staining and HP1γ foci in Wi-A treated both cancer and normal 
cells (Fig. 4-8 A-B).  Of note, since H1299 cells lacked p53 protein (Fig. 4-8 C), an 
increase in p21WAF1 was therefore attributed to p53-independent mechanism, such as 
increase in CARF, resulting in decreased levels of HDM2 and stabilization of p21WAF1 
(26;29;34;35).   
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Fig. 4-1 Dose-dependent cytotoxicity of Wi-A to human lung carcinoma and normal 
cells.  Growth curves of control and Wi-A (low- 0.2 µg/ml and high-2.0 µg/ml dose) 
treated lung carcinoma (H1299) (A).   Induction of apoptosis by high dose of Wi-A 
was confirmed by Annexin-V cytometric analysis.  As shown, increase in apoptotic 
cells was observed in cultures treated with high doses of Wi-A (B). Crystal violet 
staining of the plates showing decrease in colony forming efficiency of Wi-A (both low 
and high dose) treated cells (C).  Cell cycle analysis showed arrest of H1299, but not 
the MRC5, cells in G0/G1 (D) 
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Fig. 4-2 Low dose of Wi-A caused nuclear translocation of NFκB in lung carcinoma.  
Immunostaining of NFκB, in control and Wi-A treated cells, showed its nuclear 
translocation in cancer (H1299 and A549) cells (A & B). Normal cells (MRC5) did not 
show nuclear translocation of NFκB.  (B) Confocal images showing nuclear NFκB 
staining in cancer cells. Western blotting exhibited increase in NFκB expression in Wi-A 
treated cells (C). Cell fractionation and Western blotting analyses confirmed the nuclear 
translocation of NFκB in Wi-A treated cells (D) 
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Fig. 4-3 Upregulation of IκBα in Wi-A treated cells. Immunostaining of 
phosphorylated IκBα (A) 
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Fig. 4-4 Upregulation of p-p38MAPK in Wi-A treated cells. Immunostaining of 
phosphorylated p38MAPK (A) in control and Wi-A treated lung carcinoma and normal 
cells revealed their upregulation in cancer cells only.  Nuclear translocation of p38MAPK 
and its phosphorylation was confirmed by confocal laser scanning microscopy (B) and 
Western blotting (C) with phosphorylation specific antibody.  
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Fig. 4-5 Immunostaining and Western blotting (A, B, C) for Cyclin D1 and Cyclin E in 
control and Wi-A treated cancer and normal cells showed downregulation of Cyclin D1 
and Cyclin E cancer cells only. Normal cells showed downregulation of Cyclin E, but not 
of Cyclin D1. 
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Fig. 4-6 Upregulation of DNA damage response in Wi-A treated cancer and normal cells. 
Immunostaining of CARF, gH2AX and ROS revealed their upregulation in Wi-A treated 
both cancer and normal cells (A and B). Upregulation of p21WAF1 and p16INK4A was also 
observed both in cancer and normal cells (C and D). 
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Fig. 4-6 Upregulation of DNA damage response in Wi-A treated cancer and normal cells. 
Immunostaining of CARF, gH2AX and ROS revealed their upregulation in Wi-A treated 
both cancer and normal cells (A and B). Upregulation of p21WAF1 and p16INK4A was also 
observed both in cancer and normal cells (C and D). 
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Fig. 4-7 Downregulation of CDK4, CDK2 and pRB phosphorylation in Wi-A treated 
cancer and normal cells.  Immunostaining of CDK4, CDK2 and phosphorylated pRB 
showed their downregulation in Wi-A treated both cancer cells (A and C).  Normal cells 
showed decrease in CDK2 and phosphorylated pRB (A-C). (D) Western blotting showing 
decrease in CDK2 and phosphorylated Rb both in cancer and normal cells; CDK4 showed 
decrease in cancer cells. 
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Fig. 4-8 Induction of senescence in Wi-A treated cancer and normal cells. Senescence 
associated b-gal staining (A) and HP1g (B) foci appeared both in H1299 (p53 -/-) and 
MRC5 (p53+/+) cells subsequent to Wi-A treatment. Increase in p53 was observed in 
MRC5 cells (C). 
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Fig. 4-9 (A) Schematic diagram showing the effect of Wi-A on DNA damage signaling in 
cancer and normal cells. Whereas p38 and NFkB axis were selectively activated in cancer 
cells (shown by grey arrows), CARF and its downstream activators p53, p21WAF1 and 
p16INK4A were activated both in cancer and normal cells (shown by black arrow) resulting 
in induction of senescence.   
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Chapter 5 Conclusions and future research 
The anticancer activity of CAPE and cytotoxic doses for different cancer cell lines was 
similar with other reports (1-6). Computational and molecular analyses together support 
and revealed that CAPE targets mortalin-p53 complex interactions that are specific in 
cancer cells and hence a worth observation, at least in part, for selective toxicity of 
CAPE to cancer cells (1-6).  Furthermore, CAPE treated cells showed reduction in 
mortalin, that is enriched in cancer cells and known to promote carcinogenesis and 
metastasis, suggesting that CAPE is an anti-mortalin molecule suitable for cancer and 
metastatic therapy. 
The mechanisms of the anti-tumor activity in CAPE have not been well known. It was 
shown to suppress 12-O-tetradecanoylphorbol-13-acetate-mediated cell transformation 
and induce apoptosis in mouse epidermal cells through p53-dependent and independent 
pathways (7).  CAPE was shown to inhibit production of nitric oxide and iNOS protein 
expression which are involved in inflammatory and autoimmune-mediated tissue 
destruction induced by lipopolysaccharide (LPS) plus interferon-gamma (IFN-gamma), 
and show anti-inflammatory, anti-viral and anticancer effects (8). CAPE caused  cell 
cycle arrest and growth inhibition were shown to be mediated via activation of Skp2, 
p53, p21Cip1 and p27Kip1 proteins (9).  It was shown to inhibit NFkB, activate 
survival  MAPK family proteins p38 and JNK resulting in apoptosis (10). Anti-
metastasis activity of CAPE (decreased expression of matrix metalloproteinases) was 
supported by many studies (11-14).  Taken together and addition to these reports, I 
demonstrate that CAPE targets mortalin a stress chaperon leading to (i) growth arrest 
activation through p53-GADD45a-p21 signaling and (ii) reduction in cell migration 
through matrix metalloproteinases. I therefore investigated several cell stemness 
markers and drug resistance in mortalin overexpressing breast cancer cells.  I 
demonstrate that mortalin overexpressing cells were enriched with stemness markers 
and exhibit resistance to cytotoxicity induced by several chemotherapeutic drugs.  (iii) 
Furthermore, treatment of the cells with mortalin shRNA or inhibitors LIKE CAPE 
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reverted the drug resistance of cells and dampened their migration and invasion 
potentials.    
 Metals interfere with the biological activity of native, folded proteins by diverse 
modes of action (i) binds with other functional groups in protein or with free thiols (ii) 
catalyze oxidation of amino acid side chains (iii) displace essential metals ions (15;16). 
All things considered, it is abundantly cleared that protein aggregation or mis-folding 
is also a cause of many neurodegenerative diseases and it also regulates neuronal health 
and length. Using small molecules CAPE could be a better therapeutic approach to 
understand selective neuronal loss in the common neurodegenerative disease. 
Senescence associated b-gal and HP1g assays, indeed, endorsed Wi-A induced 
senescence both in cancer and normal cells.  The study demonstrated that Wi-A 
caused activation of DNA damage response by pleiotropic mechanisms. Although one 
axis of activated DNA damage signaling, p38MAPK-NFκB, was activated selectively 
in cancer cells, the other one, CARF-p21WAF1/p16INK4A-Cyclin/CDK-pRB was 
activated both in cancer and normal cells suggesting that CARF plays an important role 
in Wi-A induced senescence.    
 
Future research 
1.  I have established a new screening system to identify new hypoxia modulating 
small molecules. On basis of that, other identified pro-hypoxia and anti-hypoxia 
molecules will be further studied in different disease models like oxidative stress, 
cancer and aging. 
2. The current study will be extended to identify other molecular pathways and targets 
by these molecules to make a bridge in between these diseases, connecting with aging, 
which will be helpful to improve these small molecule therapeutic effects. 
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